Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma ; volume:12 ; number:3 ; year:2023 ; pages:189-197 ; extent:9
Liver cancer ; 12, Heft 3 (2023), 189-197 (gesamt 9)
- Creator
-
Kudo, Masatoshi
- DOI
-
10.1159/000531225
- URN
-
urn:nbn:de:101:1-2023081700305624532382
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kudo, Masatoshi
Other Objects (12)
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Atezolizumab (NSCLC, adjuvant) : Addendum zum Auftrag A22-67 (Dossierbewertung)
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Atezolizumab (NSCLC, adjuvant) : Addendum zum Auftrag A22-67 (Dossierbewertung)
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Atezolizumab (NSCLC, adjuvant) : Addendum zum Auftrag A22-67 (Dossierbewertung)
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Atezolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience